Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00981656 · ClinicalTrials.gov registry record · Phase 2
Radiation Therapy and Chemotherapy in Treating Patients With Stage I Bladder Cancer
A Phase 2 study, sponsored by Radiation Therapy Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 37
- Enrollment target
NCT00981656 is a Phase 2 study that has completed, run by Radiation Therapy Oncology Group. The registered enrollment target is 37 participants.
The verdict
NCT00981656, a Phase 2 study, has completed, sponsored by Radiation Therapy Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 37 participants
- Enrollment target
Study Summary
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as cisplatin, mitomycin C, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving radiation therapy together with cisplatin may kill more tumor cells. PURPOSE: This phase II trial is studying how well radiation therapy given together with chemotherapy works in treating patients with stage I bladder cancer.
Interventions
- DRUG 5-fluorouracil
- DRUG cisplatin
- DRUG Mitomycin
- RADIATION Three-Dimensional Conformal Radiation Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2009-11 |
| Est. Completion | 2023-08-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00981656
The ClinicalTrials.gov registry entry for NCT00981656 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Radiation Therapy Oncology Group, which has 144 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which 5-fluorouracil is the first listed.
NCT00981656 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00981656 about?
NCT00981656 is a clinical study titled "Radiation Therapy and Chemotherapy in Treating Patients With Stage I Bladder Cancer". RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as cisplatin, mitomycin C, and fluor...
What is the current status of trial NCT00981656?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 37 participants. The study started on 2009-11. Estimated completion is 2023-08-15.
What interventions are being tested in trial NCT00981656?
The interventions under investigation include: 5-fluorouracil (DRUG), cisplatin (DRUG), Mitomycin (DRUG), Three-Dimensional Conformal Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT00981656?
This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.